SCHEMBL10042364

SCHEMBL10042364

Cc1ccc(C(=O)CN(C)C)cc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.50
KDM4E B2RXH2 2/20 0.50
USP2 O75604 1/20 0.50
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
CYP1A2 P05177 2/20 0.41
CYP3A4 P08684 2/20 0.41
CYP2D6 P10635 2/20 0.41
CYP2C9 P11712 2/20 0.41
CYP2C19 P33261 2/20 0.41
GAA P10253 2/20 0.41
HSD17B1 P14061 3/20 0.40
CLK1 P49759 1/20 0.39
DYRK1A Q13627 1/20 0.39
DYRK1B Q9Y463 1/20 0.39
HPGD P15428 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA7 P43166 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30309743 0.85 KDM4E (0.53) ALDH1A1KDM4EUSP2MEN1KMT2A
SCHEMBL17032000 0.85 ALDH1A1 (0.53) ALDH1A1KDM4EUSP2MEN1KMT2A
SCHEMBL421462 0.85 KDM4E (0.53) ALDH1A1KDM4EUSP2MEN1KMT2A
SCHEMBL7049792 0.79 ALDH1A1 (0.50) ALDH1A1MEN1KMT2ACYP1A2CYP3A4
SCHEMBL10622910 0.79 CYP1A2 (0.44) ALDH1A1KDM4EMEN1KMT2ACYP1A2
SCHEMBL8680479 0.76 HSD17B3 (0.51) ALDH1A1MEN1KMT2ACYP1A2CYP2D6
Hydrochloric Acid SCHEMBL11269811 0.76 LCK (0.51) ALDH1A1KDM4EUSP2MEN1KMT2A
SCHEMBL18661938 0.75 HPGD (0.68) ALDH1A1MEN1KMT2ACYP1A2HPGD
SCHEMBL11631620 0.75 KMT2A (0.59) ALDH1A1MEN1KMT2ACYP1A2CYP2C19
SCHEMBL26320508 0.75 ALPG (0.48) KDM4EMEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9266817-B2 Catecholamine derivatives for obesity and neurological disorders EMORY UNIVERSITY (US) 2016-02-23 US disclosed
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-11-06 US disclosed
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS EMORY UNIVERSITY (US) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120022086-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ALDH1A1 412/4885KDM4E 2077/4885USP2 3473/4885
US-20140329907-A1 CATECHOLAMINE DERIVATIVES FOR OBESITY AND NEUROLOGICAL DISORDERS BDNF, NTRK2, COMT ALDH1A1 412/4885KDM4E 2077/4885USP2 3473/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.